In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.
Animals
Conjunctivitis, Allergic
/ chemically induced
Contact Lenses, Hydrophilic
Delayed-Action Preparations
/ administration & dosage
Dibenzazepines
/ administration & dosage
Disease Models, Animal
Drug Delivery Systems
Guinea Pigs
Histamine
/ toxicity
Histamine H1 Antagonists
/ administration & dosage
Imidazoles
/ administration & dosage
In Vitro Techniques
Male
Ophthalmic Solutions
Osmolar Concentration
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
08
2018
accepted:
20
12
2018
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
23
10
2019
Statut:
epublish
Résumé
A number of drug-releasing contact lenses are currently being studied to address issues inherent in eye drops as a drug delivery method. In this study, we developed epinastine hydrochloride-releasing daily soft contact lenses for treatment of allergic conjunctivitis and examined their in vitro and in vivo performance. Preformed soft contact lenses with/without ionic functional groups were soaked in a solution of epinastine hydrochloride in phosphate-buffered saline to prepare epinastine hydrochloride-releasing soft contact lenses. Among these contact lenses with different ionicities, anionic lenses demonstrated the maximum, relatively linear epinastine hydrochloride release, in vitro. The amount of epinastine hydrochloride release was directly proportional to the concentration of the epinastine hydrochloride solution used to prepare the contact lens. The epinastine hydrochloride-releasing anionic soft contact lens also demonstrated prolonged drug release and significantly greater efficacy compared with epinastine hydrochloride eye drops 12 h after treatment, in vivo. Further studies are required to determine the appropriate amount of epinastine hydrochloride to be contained in the anionic soft contact lenses.
Identifiants
pubmed: 30699147
doi: 10.1371/journal.pone.0210362
pii: PONE-D-18-24255
pmc: PMC6353132
doi:
Substances chimiques
Delayed-Action Preparations
0
Dibenzazepines
0
Histamine H1 Antagonists
0
Imidazoles
0
Ophthalmic Solutions
0
Histamine
820484N8I3
epinastine
Q13WX941EF
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0210362Déclaration de conflit d'intérêts
I have read the journal's policy and the authors of this manuscript have the following competing interests: Research grant from SEED CO., LTD. (Minami, Fukushima); paid employment by SEED CO., LTD. (Hino, Arai, Matsunaga). This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
Invest Ophthalmol Vis Sci. 2013 Apr 09;54(4):2551-61
pubmed: 23462746
Ophthalmic Epidemiol. 2005 Aug;12(4):233-42
pubmed: 16033744
Br J Ophthalmol. 2010 Dec;94(12):1657-61
pubmed: 20956272
Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):451-6
pubmed: 25115683
J Glaucoma. 2008 Mar;17(2):147-56
pubmed: 18344762
Eye Contact Lens. 2008 Sep;34(5):266-71
pubmed: 18779666
Optom Vis Sci. 2012 Aug;89(8):1140-9
pubmed: 22773177
J Control Release. 2003 Oct 30;92(3):259-64
pubmed: 14568407
J Control Release. 2018 Jul 10;281:97-118
pubmed: 29782944
Postepy Dermatol Alergol. 2015 Jun;32(3):204-9
pubmed: 26161062
Ann Allergy Asthma Immunol. 2014 Oct;113(4):476-81
pubmed: 25163405
Prog Retin Eye Res. 1998 Jan;17(1):33-58
pubmed: 9537794
J Control Release. 2012 Feb 10;157(3):391-7
pubmed: 21982900
Semin Ophthalmol. 2009 May-Jun;24(3):156-60
pubmed: 19437351